
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 10, 2017**

MEDICAL TRANSCRIPTION BILLING, CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

333-192989
(Commission
File Number)

22-3832302
(IRS Employer
Identification No.)

7 Clyde Road, Somerset, New Jersey, 08873
(Address of principal executive offices, zip code)

(732) 873-5133
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On May 10, 2017, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that the closing bid price of the Company's common stock has been in excess of the \$1.00 minimum requirement for the last 10 consecutive trading days, from April 26 to May 9, 2017. As a result, Nasdaq considers the matter closed and the Company will no longer need to do a reverse stock split.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Letter from Listing Qualifications Department of The Nasdaq Stock Market, dated May 11, 2017

SIGNATURE(S)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Medical Transcription Billing, Corp.

Date: May 11, 2017

By: /s/ Mahmud Haq

Mahmud Haq
Chairman of the Board and Chief Executive Officer

MTBC Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

SOMERSET, N.J. May 11, 2017 (Marketwired) — MTBC (Nasdaq: MTBC) (Nasdaq: MTBCP) a leading provider of proprietary, cloud-based electronic health records, practice management and mHealth solutions, today announced that the Company received a letter from the NASDAQ Capital Market that it has regained compliance with NASDAQ Capital Market's minimum bid price continued listing requirement. The letter highlights that for ten (10) consecutive business days the Company has had a closing bid price of \$1.00 per share or greater. NASDAQ has notified the Company that they have regained compliance with Listing Rule 5550(a)(2) and the matter is now closed. After regaining compliance, the Company announced that it will no longer need to effectuate a reverse stock split.

"News of regaining NASDAQ minimum bid price compliance is very gratifying, after announcing our Q1 2017 operating results as well as recent news of strategic relationships and new product developments," said Bill Korn, MTBC's Chief Financial Officer. "It is great to see positive feedback from the market."

About MTBC

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers throughout the United States. Our integrated Software-as-a-Service (SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC's common stock trades on the NASDAQ Capital Market under the ticker symbol "MTBC," and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol "MTBCP."

For additional information, please visit our website at www.mtbc.com.

Follow MTBC on [TWITTER](#), [LINKEDIN](#) and [FACEBOOK](#).

SOURCE MTBC

Company and Investor Contact:

Bill Korn
Chief Financial Officer
Medical Transcription Billing, Corp.
bkorn@mtbc.com
732-873-5133
